2017 ACR/ARHP Annual Meeting

November 3-8, 2017. San Diego, CA.

View by Number View by Title View Sessions

View by Date

Abstract Number: 1814

Time Trends over a Decade Show Earlier Intensified Medication Strategies and Improved Outcomes in Canadians with Early Inflammatory Arthritis
Abstract Number: 1815

Patterns of Methotrexate Use and Discontinuation in a U.S. Rheumatoid Arthritis Registry
Abstract Number: 1816

Sex Differences in Orthopedic Surgery Among Patients with Rheumatoid Arthritis
Abstract Number: 1817

Abatacept Shows Better Sustainability Than TNF Inhibitors When Used Following Initial Biologic DMARD Failure in the Treatment of RA: 8 Years of Real-World Observations from the Rhumadata® Clinical Database and Registry
Abstract Number: 1818

Development of Abatacept- and Adalimumab-Specific Predictive Models of Response to Therapy in RA Using Data from a Head-to-Head Study
Abstract Number: 1819

Delay of Diagnosis and Treatment in Seronegative Rheumatoid Arthritis: Missing the Window of Opportunity
Abstract Number: 1820

Sustained Effectiveness after Remission Induction with Methotrexate and Step-Down Glucocorticoids in Patients with Early Rheumatoid Arthritis Following a Treat-to-Target Strategy after 2 Years
Abstract Number: 1821

Dose Reduction of Baricitinib in Patients with Rheumatoid Arthritis Achieving Sustained Disease Control: Results of a Prospective Study
Abstract Number: 1822

The Effect of Sarilumab in Combination with Dmards on Fasting Glucose and Glycosylated Hemoglobin in Patients with Rheumatoid Arthritis with and without Diabetes
Abstract Number: 1823

Methotrexate Requires High Serum BAFF Levels to Prevent Immunization Against TNF-α Inhibitors
Abstract Number: 1824

Evaluation of Pneumococcal and Tetanus Vaccine Responses in Patients with Rheumatoid Arthritis Receiving Baricitinib: Results from a Long-Term Extension Trial Substudy
Abstract Number: 1825

Comparative Analysis of Achievement of Individual Important Response Measured By DAS28dcrit in a Randomized Head-to-Head Trial of Tocilizumab Vs. Adalimumab in Active Rheumatoid Arthritis
Abstract Number: 1826

Secukinumab Achievement of Psoriatic Arthritis Disease Activity Score (PASDAS) Related Remission: 2-Year Results from a Phase 3 Study
Abstract Number: 1827

Comparison of Ixekizumab and Ustekinumab Efficacy in the Treatment of Nail Lesions of Patients with Moderate-to-Severe Plaque Psoriasis: 24-Week Data from a Phase 3 Trial
Abstract Number: 1828

Secukinumab Provides Sustained Improvements in the Signs and Symptoms of Active Ankylosing Spondylitis: 2-Year Results from a Phase 3 Study

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].